Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 6
2004 8
2005 4
2006 7
2007 6
2008 6
2009 9
2010 6
2011 7
2012 9
2013 9
2014 7
2015 10
2016 11
2017 10
2018 11
2019 11
2020 12
2021 15
2022 9
2023 6
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

159 results

Results by year

Filters applied: . Clear all
Page 1
Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results.
Kantarjian H, Short NJ, Jain N, Sasaki K, Huang X, Haddad FG, Khouri I, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Kebriaei P, Garris R, Loghavi S, Jorgensen J, Kwari M, O'Brien S, Ravandi F, Jabbour E. Kantarjian H, et al. Among authors: khouri i. Am J Hematol. 2023 Mar;98(3):493-501. doi: 10.1002/ajh.26816. Epub 2023 Jan 4. Am J Hematol. 2023. PMID: 36600670 Free article.
Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia.
Gaballa MR, Banerjee P, Milton DR, Jiang X, Ganesh C, Khazal S, Nandivada V, Islam S, Kaplan M, Daher M, Basar R, Alousi A, Mehta R, Alatrash G, Khouri I, Oran B, Marin D, Popat U, Olson A, Tewari P, Jain N, Jabbour E, Ravandi F, Kantarjian H, Chen K, Champlin R, Shpall E, Rezvani K, Kebriaei P. Gaballa MR, et al. Among authors: khouri i. Blood. 2022 Mar 24;139(12):1908-1919. doi: 10.1182/blood.2021013290. Blood. 2022. PMID: 34914826 Free PMC article.
Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia.
Kantarjian H, Haddad FG, Jain N, Sasaki K, Short NJ, Loghavi S, Kanagal-Shamanna R, Jorgensen J, Khouri I, Kebriaei P, Alvarado Y, Kadia T, Paul S, Garcia-Manero G, Dabaja B, Yilmaz M, Jacob J, Garris R, O'Brien S, Ravandi F, Jabbour E. Kantarjian H, et al. Among authors: khouri i. J Hematol Oncol. 2023 May 2;16(1):44. doi: 10.1186/s13045-023-01444-2. J Hematol Oncol. 2023. PMID: 37131217 Free PMC article. Clinical Trial.
Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Jabbour E, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Kanagal-Shamanna R, Jorgensen J, Khouri IF, Kebriaei P, Jain N, Alvarado Y, Kadia TM, Paul S, Garcia-Manero G, Dabaja BS, Burger JA, DiNardo CD, Daver NA, Montalban-Bravo G, Yilmaz M, Ohanian M, Ferrajoli A, Jacob J, Rostykus M, Garris R, O'Brien S, Kantarjian HM. Jabbour E, et al. Among authors: khouri if. Cancer. 2021 Jun 15;127(12):2025-2038. doi: 10.1002/cncr.33469. Epub 2021 Mar 19. Cancer. 2021. PMID: 33740268 Free article.
Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies.
Singh H, Srour SA, Milton DR, McCarty J, Dai C, Gaballa MR, Ammari M, Olivares S, Huls H, De Groot E, Marin D, Petropoulos D, Olson AL, Anderlini P, Im JS, Khouri I, Hosing CM, Rezvani K, Champlin RE, Shpall EJ, Cooper LJN, Kebriaei P. Singh H, et al. Among authors: khouri i. Front Immunol. 2022 Nov 10;13:1032397. doi: 10.3389/fimmu.2022.1032397. eCollection 2022. Front Immunol. 2022. PMID: 36439104 Free PMC article. Clinical Trial.
Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant.
Al-Juhaishi T, Wang Y, Milton DR, Xu-Monette ZY, Jabbour E, Daher M, Im JS, Bashir Q, Iyer SP, Marin D, Olson AL, Popat U, Qazilbash M, Rondon G, Gulbis AM, Champlin RE, Young KH, Khouri IF. Al-Juhaishi T, et al. Among authors: khouri if. Bone Marrow Transplant. 2023 Sep;58(9):1000-1007. doi: 10.1038/s41409-023-02006-3. Epub 2023 May 18. Bone Marrow Transplant. 2023. PMID: 37198234
The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors.
Jabbour EJ, Sasaki K, Haddad FG, Issa GC, Garcia-Manero G, Kadia TM, Jain N, Yilmaz M, DiNardo CD, Patel KP, Kanagal-Shamanna R, Champlin R, Khouri IF, Dellasala S, Pierce SA, Kantarjian H. Jabbour EJ, et al. Among authors: khouri if. Am J Hematol. 2023 Apr;98(4):658-665. doi: 10.1002/ajh.26852. Epub 2023 Jan 31. Am J Hematol. 2023. PMID: 36683287 Free article.
Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities.
Popat UR, Pasvolsky O, Bassett R Jr, Mehta RS, Olson A, Chen J, Alousi AM, Al-Atrash G, Bashir Q, Gulbis AM, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Oran B, Saini N, Shigle TL, Srour SA, Ramdial JL, Rezvani K, Qazilbash MH, Andersson BS, Champlin RE, Shpall EJ. Popat UR, et al. Among authors: khouri i. Blood Adv. 2023 Oct 24;7(20):6196-6205. doi: 10.1182/bloodadvances.2023010850. Blood Adv. 2023. PMID: 37611156 Free PMC article. Clinical Trial.
159 results